Boniva

Osteoporosis, Malignant Neoplasms, Bone Metastases + 1 more
Treatment
2 FDA approvals
20 Active Studies for Boniva

What is Boniva

IbandronateThe Generic name of this drug
Treatment SummaryIbandronate, also known as BM 21.0955, is a type of medication used to prevent and treat bone loss in postmenopausal women. It is a third-generation drug that is similar to zoledronic acid, minodronic acid and risedronic acid. Ibandronate has been used to treat bone loss in dogs since 1993, and it was approved by the FDA in 2003.
Bonivais the brand name
image of different drug pills on a surface
Boniva Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Boniva
Ibandronate
2005
24

Approved as Treatment by the FDA

Ibandronate, otherwise known as Boniva, is approved by the FDA for 2 uses which include Osteoporosis and Osteoporosis .
Osteoporosis
Helps manage Osteoporosis
Osteoporosis
Helps manage Osteoporosis

Effectiveness

How Boniva Affects PatientsIbandronate is a medicine used to help prevent and treat osteoporosis in postmenopausal women. It is a relatively safe drug, and its effects can last a long time. Patients should be aware of the potential side effects such as stomach issues, low calcium, muscle pain, jaw damage, and kidney problems.
How Boniva works in the bodyBisphosphonates are taken into the body, where they bind to bone. This triggers the osteoclasts (cells that break down bone) to become acidic. This causes the bisphosphonates to be released from the bone and taken up by the osteoclasts. The bisphosphonates stop the osteoclasts from doing their job, which stops the bone from being broken down. Nitrogen containing bisphosphonates such as ibandronate also inhibit proteins that are important for cell survival. Without these proteins, cells die, causing tumor cells to die as well.

When to interrupt dosage

The advocated dosage of Boniva is contingent upon the diagnosed condition, including Bone Metastases, Malignant Neoplasms and Osteoporosis. The dose also fluctuates as per the method of delivery outlined in the table below.
Condition
Dosage
Administration
Malignant Neoplasms
, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous
Bone Metastases
, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous
Breast Cancer
, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous
Osteoporosis
, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous

Warnings

Boniva Contraindications
Condition
Risk Level
Notes
Esophageal Strictures
Do Not Combine
Hypocalcemia
Do Not Combine
Esophagus
Do Not Combine
Esophageal Achalasia
Do Not Combine
Orthostatic Intolerance
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Ibandronate may interact with Pulse Frequency
There are 20 known major drug interactions with Boniva.
Common Boniva Drug Interactions
Drug Name
Risk Level
Description
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mobocertinib.
Ziprasidone
Major
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone.
Abexinostat
Minor
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Abexinostat.
Aceprometazine
Minor
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aceprometazine.
Boniva Toxicity & Overdose RiskSigns of ibandronate overdose include low calcium and phosphorus levels, stomach pain, indigestion, esophagitis, and ulcers. To reduce the amount of unabsorbed drug, patients can drink milk or take antacids. Treatment for an ibandronate overdose includes providing intravenous electrolytes, and dialysis is not known to be effective in removing the drug from the bloodstream.
image of a doctor in a lab doing drug, clinical research

Boniva Novel Uses: Which Conditions Have a Clinical Trial Featuring Boniva?

At present, 729 active clinical trials are underway to ascertain the effectiveness of Boniva in ameliorating Bone Metastases, Malignant Neoplasms and Osteoporosis.
Condition
Clinical Trials
Trial Phases
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Breast Cancer
21 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Bone Metastases
7 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 3
Malignant Neoplasms
0 Actively Recruiting

Boniva Reviews: What are patients saying about Boniva?

5Patient Review
11/2/2016
Boniva for Decreased Bone Mass Following Menopause
I've been on Boniva for four weeks now, and I'm happy to report that I haven't experienced any negative side effects.
2.3Patient Review
4/12/2019
Boniva for Decreased Bone Mass Following Menopause
I haven't been able to tell if it's effective yet or not. I just took my third dose, and if it's anything like the first two doses, I won't be taking it again.
2Patient Review
7/31/2021
Boniva for Decreased Bone Mass Following Menopause
I started taking Benlista a few days ago and have had some unpleasant side effects every day since then. Really terrible headaches, nausea, dizziness, and it's hard to swallow the pill. I would never recommend this medication to anyone.
1.7Patient Review
5/31/2018
Boniva for Decreased Bone Mass Following Menopause
The flu-like symptoms I experienced while taking this medication for two months were not worth the treatment.
1.7Patient Review
6/12/2021
Boniva for Decreased Bone Mass Following Menopause
I took this medicine two days ago and have been bedridden since. I'm experiencing pain all over my body at this point. There's no way I'm taking this again – the side effects are far worse than any potential benefits.
1.7Patient Review
7/2/2022
Boniva for Decreased Bone Mass Following Menopause
The generic version of Bonita gave me some pretty bad side effects that I'm still feeling even days later. Tylenol has only been managing the pain, and it's been really rough. My doctor agreed that this isn't a medication worth taking again.
1.7Patient Review
12/4/2018
Boniva for Decreased Bone Mass Following Menopause
After three months of taking this medication, I can say with certainty that I will not be continuing it for a fourth month. It has caused me immense pain in my fingers and legs, as well as severe hip joint pain.
1Patient Review
12/10/2015
Boniva for Decreased Bone Mass Following Menopause
I was given this drug by my doctor and have been taking it for 12 years . I was only supposed to take it for two years, but my GP never informed me. I was suffering from a lot of bone pain--the pain in my feet was affecting my driving, hand pain, back pain. I stopped taking Boniva two months ago and all my pains have gone away. I feel so much better.... Pain free
1Patient Review
4/22/2016
Boniva for Decreased Bone Mass Following Menopause
I took one Boniva pill on April 20th, and the next day I experienced incredibly painful symptoms in my arms, legs, and fingers. My vision was also blurred to the point where driving was not an option. Needless to say, I will not be taking this medication again.
1Patient Review
8/9/2018
Boniva for Decreased Bone Mass Following Menopause
I had some side effects the first month, but nothing major. The second month was a different story--I experienced horrible pain, dizziness, and vomiting. There's no way I'm taking it for a third month!
1Patient Review
3/8/2017
Boniva for Decreased Bone Mass Following Menopause
I would not recommend this medicine to anyone. The side effects are incredibly dangerous and potentially deadly--even before you have osteoporosis!
1Patient Review
11/3/2016
Boniva for Decreased Bone Mass Following Menopause
I experienced horrible side effects that made me feel like I was hit by a truck. The pain was excruciating and widespread. I also had to go to the hospital because of disfiguring swelling in my face and neck. I would never recommend this treatment to anyone.
1Patient Review
6/19/2018
Boniva for Decreased Bone Mass Following Menopause
I took one pill and the side effects were so bad that I decided it wasn't worth it, even if the treatment actually worked! My whole body was aching, especially my legs, arms, and fingers.
1Patient Review
6/4/2022
Boniva for Decreased Bone Mass Following Menopause
I took the recommended dosage and within two hours, I was in immense pain with heartburn. I also had diarrhea, nausea, a headache, and felt cold. For three days after taking this medication, I was housebound because of how weak and fatigued it made me feel!
1Patient Review
5/1/2022
Boniva for Post-Menopausal Osteoporosis Prevention
I followed the directions to a tee and started experiencing awful nausea and sharp abdominal pains. This continued on for weeks, including vomiting and gastritis. Save yourself the trouble and avoid this medication entirely.
1Patient Review
7/12/2018
Boniva for Decreased Bone Mass Following Menopause
I've just started taking Ibandronate, which is the generic form of Boniva. So far there have been no side effects that I can tell. My pharmacist did suggest that I continue taking a supplement called OsteoBase in addition to the Ibandronate, so I'm doing that.
1Patient Review
3/13/2022
Boniva for Decreased Bone Mass Following Menopause
I had extremely unpleasant gastrointestinal symptoms after taking just one pill. I'll be seeking an alternative from my doctor tomorrow.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about boniva

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why was Boniva taken off the market?

"Some people are worried about the possible risks of taking bisphosphonates (such as Boniva) for a long time. Some potential risks include atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer."

Answered by AI

What is better Boniva or Fosamax?

"Although both Fosamax and Boniva have been shown to reduce the risk of fractures, Fosamax is generally recommended over Boniva because it is not clear whether Boniva is effective in reducing the risk of hip or nonvertebral fractures."

Answered by AI

How effective is Boniva for osteoporosis?

"After 2 years of treatment, the average spine BMD results were 3.1% to 4.12% better for women given Boniva than for those given a placebo, meaning Boniva is effective in preventing osteoporosis for postmenopausal women."

Answered by AI

What are the side effects from taking Boniva?

"The pill's most common side effects are diarrhea, pain in the extremities, and upset stomach. Its less common side effects may be pain or trouble swallowing, heartburn, and stomach ulcers."

Answered by AI

Clinical Trials for Boniva

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Algorithm-Based Treatment Options for Advanced Breast Cancer

18 - 120
All Sexes
Bethesda, MD
Background: Breast cancer is the most common cancer in US women. There are different types of breast cancers; some are aggressive and difficult to treat. Researchers want to know if an algorithm (ENLIGHT) can help choose approved drugs that will treat these cancers more effectively. Objective: To test whether ENLIGHT can find better treatments for aggressive breast cancers. Eligibility: People aged 18 years and older with triple-negative or endocrine therapy resistant breast cancer; the cancer must have either failed to respond to treatment or come back after treatment. Design: Participants will be screened. A sample of tissue taken from the tumor will be tested using ENLIGHT as well as another method (TruSight Oncology 500). Participants will be assigned to 1 of 3 groups based on the algorithm search results: Group 1: No drug option was recommended. Participants will continue with their standard treatment with their local doctors. Group 2: A drug already approved for the participant's disease was recommended, but the participant has not yet received it. These results will be sent to the participant's local doctors. Participants may return to the NIH if their disease gets worse after using the suggested drugs. Group 3: A drug approved for other uses was recommended. Participants will be treated with the recommended drugs at the NIH; their care will be managed by an NIH doctor. They will continue to receive treatment as long as the drugs are helping them. They will have follow-up visits for 2 years after treatment ends. Participants who are not treated at the NIH will be contacted for a check on their health every 3 months for 2 years.
Waitlist Available
Has No Placebo
National Institutes of Health Clinical CenterPadma S Rajagopal, M.D.
Image of Washington University School of Medicine in Saint Louis, United States.

ChatGPT Education for Breast Reconstruction in Breast Cancer

18+
All Sexes
Saint Louis, MO
In this study, patients who are scheduled for breast reconstruction consultation will be randomized into the intervention group (ChatGPT-generated patient education regarding possible reconstruction options) or the control group (usual patient education). All patients will complete a survey following their in-person consultation to assess their experience and overall satisfaction with the consultation process. Additionally, participating surgeons will complete a separate survey to evaluate their consultation experience, satisfaction, and to assess the accuracy and clinical utility of the ChatGPT-generated patient education materials. The surveys are designed to gather information on patient characteristics, organizational health literacy according to Brega et al. Other survey questions have been designed to meet the outcomes of this study and have not been based on previously published surveys.
Recruiting
Has No Placebo
Washington University School of Medicine (+1 Sites)Saif M Badran, M.D., Ph.D., FRCS
Have you considered Boniva clinical trials? We made a collection of clinical trials featuring Boniva, we think they might fit your search criteria.Go to Trials
Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD
Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.
Waitlist Available
Has No Placebo
University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)Denise Orwig, PhD
Have you considered Boniva clinical trials? We made a collection of clinical trials featuring Boniva, we think they might fit your search criteria.Go to Trials
Have you considered Boniva clinical trials? We made a collection of clinical trials featuring Boniva, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security